Addiction is not simply a chronic brain disease and considering it as such can limit treatment options and increase stigma, an extensive research review suggests.
Novo Nordisk to invest $4.1bn in manufacturing facility in Clayton
Preparatory work has commenced on the 56-acre site, with construction expected to be completed between 2027 and 2029. Credit: © 2024 Novo Nordisk A/S. Novo